{"hands_on_practices": [{"introduction": "The initial encounter with a patient presenting with thrombotic microangiopathy (TMA) is a high-stakes clinical scenario requiring rapid assessment and decisive action. This exercise simulates that crucial first step, where you must differentiate between the most urgent life-threat, thrombotic thrombocytopenic purpura (TTP), and other causes like atypical hemolytic uremic syndrome (aHUS). By calculating the PLASMIC score, you will practice using a validated clinical prediction tool to stratify risk and justify empiric therapy while awaiting definitive diagnostic results, a core skill in emergency medicine and hematology [@problem_id:4799984].", "problem": "A $42$-year-old adult presents with acute onset fatigue, easy bruising, and new confusion. Physical examination reveals mild scleral icterus and scattered petechiae. The patient has no history of solid organ or stem cell transplant, and no known or suspected active cancer. There is no history of diarrheal illness. Initial laboratory findings are:\n- Platelet count: $22 \\times 10^{9}$/L\n- Hemoglobin: $9.8$ g/dL\n- Mean corpuscular volume: $88$ fL\n- Lactate dehydrogenase: $1{,}100$ U/L\n- Indirect bilirubin: $2.4$ mg/dL\n- Haptoglobin: undetectable\n- Reticulocyte percentage: $5.1\\%$\n- Creatinine: $2.3$ mg/dL\n- Prothrombin time: $12$ seconds; International normalized ratio: $1.1$\n- Peripheral blood smear: $3+$ schistocytes\n\nA thrombotic microangiopathy due to either thrombotic thrombocytopenic purpura (TTP) or atypical hemolytic uremic syndrome (aHUS) is suspected. The A Disintegrin And Metalloprotease with Thrombospondin type $1$ motif, member $13$ (ADAMTS13) activity assay has been sent but the result will take $48$â€“$72$ hours.\n\nUsing the established PLASMIC criteria widely employed to predict severe ADAMTS13 deficiency, assign $1$ point for each of the following present features and $0$ points otherwise:\n- Platelet count $ 30 \\times 10^{9}$/L.\n- Hemolysis variable present (any laboratory evidence of microangiopathic hemolysis such as elevated lactate dehydrogenase, indirect hyperbilirubinemia, undetectable haptoglobin, reticulocytosis, or schistocytosis).\n- No active cancer.\n- No solid organ or stem cell transplant.\n- Mean corpuscular volume $ 90$ fL.\n- International normalized ratio $ 1.5$.\n- Creatinine $ 2.0$ mg/dL.\n\nCompute the total PLASMIC score from the provided data. Then, starting from fundamental pathophysiology of thrombotic microangiopathy and well-tested clinical facts about time-to-result and treatment impact, explain why a high PLASMIC score justifies empiric plasma exchange while ADAMTS13 activity results are pending, explicitly distinguishing the rationale from the management principles of atypical hemolytic uremic syndrome. Provide the PLASMIC score as a pure number with no units; no rounding is required.", "solution": "The solution requires two parts: calculating the PLASMIC score and explaining the rationale for the subsequent clinical action.\n\n**Part 1: PLASMIC Score Calculation**\n\nThe PLASMIC score is calculated by assigning one point for each of the seven criteria that are met by the patient's data.\n\n1.  **Platelet count $ 30 \\times 10^{9}$/L:** The patient's count is $22 \\times 10^{9}$/L. This is less than 30, so this criterion is met. **(1 point)**\n2.  **Hemolysis variable present:** The patient has multiple signs of hemolysis, including elevated LDH, elevated indirect bilirubin, undetectable haptoglobin, reticulocytosis, and schistocytes. This criterion is met. **(1 point)**\n3.  **No active cancer:** The problem states there is no known or suspected active cancer. This criterion is met. **(1 point)**\n4.  **No solid organ or stem cell transplant:** The problem states there is no history of transplant. This criterion is met. **(1 point)**\n5.  **Mean corpuscular volume (MCV) $ 90$ fL:** The patient's MCV is $88$ fL. This is less than 90, so this criterion is met. **(1 point)**\n6.  **International normalized ratio (INR) $ 1.5$:** The patient's INR is $1.1$. This is less than 1.5, so this criterion is met. **(1 point)**\n7.  **Creatinine $ 2.0$ mg/dL:** The patient's creatinine is $2.3$ mg/dL. This is not less than 2.0, so this criterion is not met. **(0 points)**\n\nSumming the points gives the total PLASMIC score:\n$1 + 1 + 1 + 1 + 1 + 1 + 0 = 6$.\n\n**Part 2: Rationale for Empiric Plasma Exchange**\n\nA PLASMIC score of 6 indicates a high probability (typically $>70\\%$) of severe ADAMTS13 deficiency, which is the defining feature of thrombotic thrombocytopenic purpura (TTP). TTP is a medical emergency with a mortality rate exceeding $90\\%$ if left untreated. The justification for immediate empiric plasma exchange (PEX) is based on this high pre-test probability and the time-critical nature of the disease.\n\n*   **Distinct Pathophysiology:** TTP is caused by the inability to cleave ultra-large von Willebrand factor multimers due to a lack of ADAMTS13, leading to spontaneous platelet aggregation. In contrast, atypical HUS (aHUS) is caused by uncontrolled complement activation damaging endothelial cells.\n*   **Urgency and Treatment Efficacy:** The definitive test (ADAMTS13 activity) takes days to return. A delay in treating TTP would be catastrophic. The first-line treatment for TTP is PEX, which works by both removing the pathogenic anti-ADAMTS13 autoantibodies and replenishing the deficient ADAMTS13 enzyme. This directly reverses the underlying pathology of TTP.\n*   **Risk-Benefit Analysis:** Given a high PLASMIC score, the high likelihood of TTP makes immediate PEX a life-saving intervention. The benefit of preventing death or irreversible organ damage (like stroke) in a patient with TTP far outweighs the risks of PEX in a patient who might ultimately have aHUS.\n*   **Contrast with aHUS Management:** The primary treatment for aHUS is complement inhibition (e.g., eculizumab), not PEX. If the ADAMTS13 result later returns as normal ($>10\\%$), TTP is excluded, PEX would be stopped, and treatment would be pivoted to a C5 inhibitor for a diagnosis of aHUS.\n\nIn summary, a PLASMIC score of 6 provides a strong, evidence-based rationale to bridge the diagnostic delay by starting empiric PEX for the most likely and most imminently lethal diagnosis, TTP.", "answer": "$$\\boxed{6}$$", "id": "4799984"}, {"introduction": "Following initial stabilization, the focus of managing a TMA shifts to interpreting definitive diagnostic tests to confirm the underlying etiology and tailor therapy accordingly. This practice scenario places you at this critical pivot point, where new laboratory data, including ADAMTS13 activity and complement levels, become available. This exercise will challenge you to synthesize these results to confidently diagnose complement-mediated aHUS, discontinue ineffective empiric treatments, and initiate urgent, life-saving C5 inhibitor therapy, a process that exemplifies modern, mechanism-based medicine [@problem_id:4799985].", "problem": "A $42$-year-old man presents with $3$ days of fatigue, new-onset hypertension, and decreased urine output. He underwent a living-donor kidney transplant $8$ months ago and is maintained on tacrolimus, mycophenolate mofetil, and low-dose prednisone. Examination shows blood pressure $168/102\\,\\text{mmHg}$, mild pallor, and trace edema; there are no focal neurological deficits. Laboratory evaluation demonstrates hemoglobin $7.9\\,\\text{g/dL}$, platelet count $48\\times 10^{9}/\\text{L}$, creatinine $4.0\\,\\text{mg/dL}$ (baseline $1.4\\,\\text{mg/dL}$), lactate dehydrogenase $1{,}150\\,\\text{U/L}$, indirect bilirubin $2.0\\,\\text{mg/dL}$, undetectable haptoglobin, and a negative direct antiglobulin test. Coagulation studies show prothrombin time and activated partial thromboplastin time within normal limits and fibrinogen $350\\,\\text{mg/dL}$. Urinalysis reveals $2+$ protein and microscopic hematuria. Peripheral blood smear demonstrates $3$ to $5$ schistocytes per high-power field. He was empirically started on daily therapeutic plasma exchange upon admission for suspected thrombotic thrombocytopenic purpura.\n\nAdditional results return: ADAMTS13 (A Disintegrin And Metalloproteinase with ThromboSpondin type $1$ motif, member $13$) activity $12\\%$ with no detectable inhibitor, stool testing negative for Shiga toxin by polymerase chain reaction, complement component $3$ (C3) low at $54\\,\\text{mg/dL}$, complement component $4$ (C4) normal at $26\\,\\text{mg/dL}$. There is no fever, and mental status is normal.\n\nUsing fundamental definitions and well-tested clinical facts about thrombotic microangiopathy pathophysiology, select the most appropriate immediate management plan.\n\nA. Continue daily therapeutic plasma exchange and high-dose glucocorticoids while awaiting repeat ADAMTS13 testing; defer complement blockade until genetic studies return\n\nB. Discontinue plasma exchange now that severe ADAMTS13 deficiency is excluded; urgently initiate terminal complement blockade with a C5 inhibitor (for example, eculizumab or ravulizumab) after administering meningococcal vaccination or immediate antibiotic prophylaxis; discontinue the calcineurin inhibitor; provide supportive care including blood pressure control and renal support as needed\n\nC. Treat as Shiga toxin-producing Escherichia coli hemolytic uremic syndrome with antibiotics (for example, azithromycin) and observation, as low C3 can occur with infection\n\nD. Initiate full-dose anticoagulation for presumed disseminated intravascular coagulation and avoid complement inhibition because of infection risk\n\nE. Continue plasma exchange and add rituximab to target anti-ADAMTS13 autoantibodies because ADAMTS13 activity is low, then reconsider complement inhibition if no response", "solution": "The patient presents with the classic triad of thrombotic microangiopathy (TMA): microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and acute end-organ injury (severe acute kidney injury in a transplant recipient). The key task is to determine the specific cause of the TMA to guide immediate therapy.\n\n**Diagnostic Reasoning:**\n\n1.  **Exclude Thrombotic Thrombocytopenic Purpura (TTP):** TTP is defined by severe deficiency of ADAMTS13 activity (typically $10\\%$). The patient's ADAMTS13 activity is $12\\%$. Although this is at the lower end of the normal range, it is definitively above the diagnostic threshold for TTP. Therefore, TTP is ruled out.\n2.  **Exclude Shiga toxin-producing *E. coli* HUS (STEC-HUS):** This is ruled out by the negative stool test for Shiga toxin.\n3.  **Confirm Atypical HUS (aHUS):** After excluding TTP and STEC-HUS, the diagnosis is aHUS. This is strongly supported by the specific pattern of complement consumption: a low C3 level with a normal C4 level. This serological finding is the hallmark of alternative complement pathway overactivation, the underlying mechanism of aHUS.\n4.  **Identify the Trigger:** In a kidney transplant recipient, TMA is often precipitated by triggers. In this case, the calcineurin inhibitor (tacrolimus) is a well-known cause of drug-induced TMA and can also trigger underlying complement-mediated aHUS. The transplant itself is also a major inflammatory trigger.\n\n**Management Strategy and Option Analysis:**\n\n*   **A. Continue daily therapeutic plasma exchange...:** Incorrect. Plasma exchange is the treatment for TTP, which has been excluded. Deferring definitive therapy for aHUS (complement blockade) risks irreversible graft failure.\n*   **B. Discontinue plasma exchange... urgently initiate terminal complement blockade...:** Correct. This plan follows the diagnosis precisely. With TTP excluded, ineffective plasma exchange should be stopped. The confirmed diagnosis of complement-mediated aHUS requires urgent treatment with a C5 inhibitor (e.g., eculizumab) to halt endothelial damage and preserve the kidney transplant. It is also crucial to remove the potential trigger (the calcineurin inhibitor) and to provide mandatory prophylaxis (meningococcal vaccination/antibiotics) for C5 inhibition.\n*   **C. Treat as STEC-HUS...:** Incorrect. STEC-HUS has been definitively ruled out by laboratory testing.\n*   **D. Initiate full-dose anticoagulation...:** Incorrect. The patient's normal coagulation studies rule out disseminated intravascular coagulation (DIC). Anticoagulation is contraindicated with severe thrombocytopenia. Avoiding life-saving C5 inhibition is inappropriate.\n*   **E. Continue plasma exchange and add rituximab...:** Incorrect. This strategy is for immune-mediated TTP. Rituximab targets B-cells that produce autoantibodies, which are not implicated here (no ADAMTS13 inhibitor detected).\n\nTherefore, the most appropriate immediate management is to stop ineffective empiric therapy and start targeted, mechanism-based therapy for aHUS.", "answer": "$$\\boxed{B}$$", "id": "4799985"}, {"introduction": "Effective long-term management of aHUS extends beyond initial diagnosis and treatment initiation. Clinicians must be equipped to handle complex scenarios, such as breakthrough hemolysis, where the disease reactivates despite ongoing therapy. This advanced practice explores such a case, integrating clinical signs of TMA relapse with crucial pharmacokinetic and pharmacodynamic data. By analyzing drug trough levels and functional complement activity, you will learn to diagnose incomplete complement blockade and formulate an evidence-based strategy to regain control of the disease, reinforcing the principles of therapeutic drug monitoring in the context of a potent biological trigger [@problem_id:4799964].", "problem": "A $32$-year-old woman with a genetically confirmed diagnosis of atypical hemolytic uremic syndrome (aHUS) started eculizumab 900 mg weekly for $4$ weeks, then received 1200 mg at week $5$. She is on 1200 mg every $2$ weeks maintenance. On day $3$ of week $7$, she presents with dark urine, new fatigue, and fever. She reports an upper respiratory tract illness beginning $2$ days ago. Vital signs show a temperature of $38.5^{\\circ}\\mathrm{C}$ and blood pressure of $142/88$ mmHg. Laboratory studies reveal: hemoglobin $8.1$ g/dL (previous visit $10.5$ g/dL), platelets $85 \\times 10^{9}/\\mathrm{L}$ (previous $160 \\times 10^{9}/\\mathrm{L}$), lactate dehydrogenase $980$ U/L (elevated), undetectable haptoglobin, creatinine $2.1$ mg/dL (baseline $1.6$ mg/dL), and schistocytes on smear. Nucleic acid testing is positive for influenza A. Pharmacokinetic/pharmacodynamic monitoring obtained just before presentation shows an eculizumab trough concentration of $35$ $\\mu$g/mL and a total complement hemolytic activity (CH50) of $25\\%$ of normal (detectable). Meningococcal vaccination is up to date and she is on antibiotic prophylaxis.\n\nUsing core principles of complement biology and drug mechanism, determine the most appropriate immediate management of this suspected breakthrough hemolysis/thrombotic microangiopathy event in the context of week $7$ eculizumab therapy, the provided trough level, the CH50 result, and the intercurrent infection.\n\nA. Administer an immediate supplemental eculizumab 1200 mg dose today and temporarily shorten the maintenance interval to weekly during the infection, while treating the infection; recheck trough and CH50 in $1$ week to guide return to every $2$ weeks.\n\nB. Defer any changes; give the routinely scheduled maintenance dose later today and continue every $2$ weeks because week $7$ is within the standard maintenance window.\n\nC. Switch immediately to ravulizumab without giving an additional eculizumab dose, as breakthrough events indicate eculizumab failure.\n\nD. Initiate urgent plasma exchange to remove circulating complement components and resume eculizumab next week once hemolysis subsides.\n\nE. Add high-dose corticosteroids to suppress complement activation and continue the current eculizumab schedule unchanged.", "solution": "The patient, who has a known diagnosis of aHUS, is presenting with a clinical and laboratory relapse of thrombotic microangiopathy (TMA), as evidenced by falling hemoglobin and platelets, rising creatinine, and markers of hemolysis (elevated LDH, undetectable haptoglobin, schistocytes). This is occurring in the context of an influenza A infection, a potent trigger for complement activation.\n\n**Pathophysiological and Pharmacological Reasoning:**\n\nThe central issue is to determine why the patient is having a breakthrough TMA event despite being on maintenance eculizumab therapy. The provided pharmacokinetic (PK) and pharmacodynamic (PD) data are key:\n1.  **Pharmacokinetics (PK):** The eculizumab trough concentration is $35 \\, \\mu\\text{g/mL}$. The therapeutic target for complete C5 blockade, especially in high-risk patients, is generally considered to be $>50-100 \\, \\mu\\text{g/mL}$. This level is suboptimal.\n2.  **Pharmacodynamics (PD):** The total hemolytic complement (CH50) is $25\\%$ of normal. A CH50 assay measures the function of the entire complement cascade, which culminates in the formation of the C5b-9 membrane attack complex. Complete blockade of C5 by eculizumab should render the CH50 undetectable (or near zero). A detectable CH50 is direct functional evidence that there is incomplete terminal complement blockade, allowing complement-mediated hemolysis to occur.\n\nThe conclusion is that the massive complement activation triggered by the influenza infection has overwhelmed the patient's standard eculizumab dose, leading to a state of insufficient C5 inhibition and subsequent disease relapse.\n\n**Management Strategy and Option Analysis:**\n\n*   **A. Administer an immediate supplemental eculizumab...:** Correct. This is the most logical and evidence-based approach. An immediate supplemental dose is needed to rapidly increase drug levels and re-establish complete C5 blockade. Temporarily increasing the dosing frequency (e.g., to weekly) is necessary to maintain adequate drug levels until the infectious trigger resolves. Monitoring PK/PD levels will guide the return to the standard schedule.\n*   **B. Defer any changes...:** Incorrect. This is dangerous. The patient has active, organ-damaging TMA, and the current regimen is proven to be insufficient. Waiting for the next scheduled dose would allow the disease process to continue unabated.\n*   **C. Switch immediately to ravulizumab...:** Incorrect. While ravulizumab is another C5 inhibitor, the immediate problem is underdosing, not drug failure. The fastest and most direct way to regain control is to give more of the current drug. Switching therapies in an acute crisis is not the standard approach.\n*   **D. Initiate urgent plasma exchange...:** Incorrect. Plasma exchange is not the primary therapy for aHUS, especially when the issue is known to be incomplete C5 blockade. Stopping eculizumab is the opposite of the required action.\n*   **E. Add high-dose corticosteroids...:** Incorrect. Corticosteroids have no proven efficacy in controlling complement activation in aHUS. The fundamental problem of insufficient eculizumab dosing is not addressed by this strategy.\n\nThe management must directly target the cause of the breakthrough: insufficient drug levels for the high-demand state.", "answer": "$$\\boxed{A}$$", "id": "4799964"}]}